Sugi Predict

Sugi Predict / Compounds / SCHEMBL144194

SCHEMBL144194

SCHEMBL144194

Cc1cncc(B(O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 1/20 0.43
▸ CA2 P00918 1/20 0.42
▸ LPL P06858 1/20 0.42
▸ LIPG Q9Y5X9 1/20 0.42
▸ ATM Q13315 1/20 0.39
▸ ACHE P22303 1/20 0.35
▸ CYP2A6 P11509 4/20 0.34
▸ ORAI1 Q96D31 1/20 0.32
▸ ORAI2 Q96SN7 1/20 0.32
▸ ORAI3 Q9BRQ5 1/20 0.32
▸ TRPV6 Q9H1D0 1/20 0.32
▸ SMYD3 Q9H7B4 1/20 0.30
▸ GRM5 P41594 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30941538 1.00 HCAR2 (0.43) HCAR2CA2LPLLIPGATM
SCHEMBL15926784 0.84 HCAR2 (0.42) HCAR2CA2LPLLIPGATM
SCHEMBL5339278 0.82 HCAR2 (0.41) HCAR2CA2LPLLIPGATM
SCHEMBL28967087 0.82 ENPP2 (0.36) CA2LPLLIPG
SCHEMBL18417966 0.78 HCAR2 (0.40) HCAR2ATMCYP2A6GRM5
SCHEMBL28203596 0.77 ATM (0.38) HCAR2ATMCYP2A6
SCHEMBL30143380 0.76 TRPV1 (0.36) —
SCHEMBL31664613 0.76 TRPV1 (0.36) —
SCHEMBL2556210 0.76 CA2 (0.48) HCAR2CA2LPLLIPGCYP2A6
SCHEMBL2560130 0.74 CYP11B2 (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 659 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112687878-B Electrochemical device and electronic device 东莞新能源科技有限公司 2022-08-30 — — CN claimed
CN-112687878-A Electrochemical device and electronic device 东莞新能源科技有限公司 2021-04-20 — — CN claimed
CN-106636043-B Method for producing protease 广州立白企业集团有限公司 2020-04-07 — — CN claimed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO disclosed
EP-4735430-A1 MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2026-05-06 — — EP disclosed
EP-4212523-B1 PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2026-05-06 — — EP disclosed
EP-4727591-A1 SMARCA2 DEGRADERS AND USES THEREOF Astrazeneca AB (SE) 2026-04-22 — — EP disclosed
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS GIVAUDAN SA (CH) 2026-04-16 — — US disclosed
US-20260098036-A1 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2026-04-09 — — US disclosed
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 — — US disclosed
EP-4703359-A1 IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-03-04 — — EP disclosed
US-20090098218-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2009-04-16 — — US disclosed
WO-2009020642-A1 PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2009-02-12 — — WO disclosed
WO-2009020642-A1 PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2009-02-12 — — WO disclosed
WO-2009010488-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS NOVARTIS AG (CH) 2009-01-22 — — WO disclosed
US-20070287692-A1 ASPARTYL PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2007-12-13 — — US disclosed
EP-1778634-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2007-05-02 — — EP disclosed
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GILLESPIE PAUL 2006-06-08 — — US disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 — — WO disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS TRPM8, TRPM7, TRPM5 HCAR2 424/4885CA2 184/4885LPL 2835/4885
US-20260098036-A1 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER AHR, CBR1, CNR1 HCAR2 10/4885CA2 1179/4885LPL 4105/4885
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GYS2, GYS1, GSK3A HCAR2 93/4885CA2 574/4885LPL 616/4885
US-20070287692-A1 ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, BACE1 HCAR2 1799/4885CA2 1010/4885LPL 537/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 HCAR2 1132/4885CA2 277/4885LPL 2815/4885
US-20090098218-A1 Tetracyclic Lactame Derivatives TNF, RPS6KB2, RPS6KA2 HCAR2 989/4885CA2 3768/4885LPL 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.